NCH2.DENCH2.DEXETRA
Loading
EBITDA Over TimeExpanding
Percentile Rank80
3Y CAGR+32.0%
5Y CAGR+2.3%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+32.0%/yr
Annual compound
5Y CAGR
+2.3%/yr
Recent acceleration
Percentile
P80
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$35.00M+75.0%
2024$20.00M-52.8%
2023$42.40M+178.4%
2022$15.23M-50.2%
2021$30.55M-2.1%
2020$31.21M-